Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

 

Press Releases

15 October 2021

Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <..

4 October 2021

Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster ..

1 October 2021

BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-On..

Press releases (more)

Upcoming Events

November 1 - November 3, 2021

Citi China Investor Conference

November 9, 2021 at 8:00 AM EST

Third Quarter 2021 Earnings Call

November 16 - November 18, 2021

Jefferies London Healthcare Conference

Upcoming events (more)

Stock Quote

Oct 17, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.